home / stock / nuvb / nuvb quote
Last: | $3 |
---|---|
Change Percent: | -1.31% |
Open: | $3.09 |
Close: | $3 |
High: | $3.15 |
Low: | $2.91 |
Volume: | 1,900,600 |
Last Trade Date Time: | 06/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3 | $3.09 | $3 | $3.15 | $2.91 | 1,900,600 | 06-24-2024 |
$3.05 | $3.04 | $3.05 | $3.07 | $2.965 | 3,327,973 | 06-21-2024 |
$3.03 | $2.9 | $3.03 | $3.055 | $2.9 | 1,418,097 | 06-20-2024 |
$2.9 | $2.9 | $2.9 | $2.94 | $2.84 | 1,065,112 | 06-19-2024 |
$2.9 | $2.9 | $2.9 | $2.94 | $2.84 | 1,065,112 | 06-18-2024 |
$2.93 | $3.01 | $2.93 | $3.04 | $2.91 | 839,098 | 06-17-2024 |
$3.02 | $3.16 | $3.02 | $3.26 | $2.985 | 1,358,312 | 06-14-2024 |
$2.99 | $2.92 | $2.99 | $3.015 | $2.88 | 840,726 | 06-13-2024 |
$2.92 | $2.98 | $2.92 | $3.025 | $2.88 | 856,408 | 06-12-2024 |
$2.85 | $2.87 | $2.85 | $2.968 | $2.81 | 1,318,799 | 06-11-2024 |
$2.9 | $2.76 | $2.9 | $3.015 | $2.76 | 1,672,038 | 06-10-2024 |
$2.77 | $2.86 | $2.77 | $2.87 | $2.725 | 1,572,990 | 06-07-2024 |
$2.91 | $2.79 | $2.91 | $2.975 | $2.7898 | 2,182,544 | 06-06-2024 |
$2.8 | $2.63 | $2.8 | $2.82 | $2.57 | 2,411,993 | 06-05-2024 |
$2.61 | $2.72 | $2.61 | $2.78 | $2.58 | 1,028,436 | 06-04-2024 |
$2.72 | $3.12 | $2.72 | $3.2199 | $2.69 | 1,436,174 | 06-03-2024 |
$3.1 | $3.01 | $3.1 | $3.135 | $3.01 | 5,095,647 | 05-31-2024 |
$2.99 | $2.94 | $2.99 | $3.08 | $2.92 | 893,372 | 05-30-2024 |
$2.92 | $2.91 | $2.92 | $2.96 | $2.84 | 1,314,474 | 05-29-2024 |
$2.96 | $3.1 | $2.96 | $3.175 | $2.95 | 1,069,909 | 05-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Nuvation Bio Inc. Class A Company Name:
NUVB Stock Symbol:
NYSE Market:
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at t...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder, President, and Chief Executive Officer of Nu...
Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at...